Detalles de la búsqueda
1.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981892
2.
Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies.
Biol Blood Marrow Transplant
; 26(6): 1113-1118, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068095
3.
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Eur J Haematol
; 105(3): 335-343, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32441419
4.
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Hematol Oncol
; 37(3): 291-295, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31050810
5.
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Qual Life Res
; 27(6): 1545-1554, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29520559
6.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Ann Hematol
; 96(3): 387-391, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27889820
7.
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Am J Hematol
; 91(3): 318-21, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26748894
8.
Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Antimicrob Agents Chemother
; 57(6): 2596-602, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529741
9.
Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Cancer
; 118(2): 404-9, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21692060
10.
Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.
Transfusion
; 50(11): 2432-46, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20553434
11.
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Cancer Med
; 6(6): 1233-1239, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28544749
12.
High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.
Thromb Res
; 156: 168-171, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28662484
13.
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Oncotarget
; 8(45): 79073-79086, 2017 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29108288
14.
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.
Leuk Res
; 69: 18-23, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29625320
15.
Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome.
Blood
; 102(6): 2014-20, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12791662
Resultados
1 -
15
de 15
1
Próxima >
>>